Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant in pediatric episodic migraine
NL-OMON60560Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atogepant in episodic migraine, sponsored by AbbVie Inc. Primary endpoint: Change from baseline in mean monthly migraine days across the 12-week treatment period. Started Nov 2023; status: recruiting.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NL-OMON60560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60560.